BEAT THE STREET GAME:
ASCO Abstract Preview: ImClone, Genentech
The American Society of Clinical Oncology, for the first time, is making research abstracts freely available to everyone ahead of the cancer drug confab. Here's a cheat sheet.
Related Topics: Drugs | Health Care | Biotech
06:59AM 05/08/08
Onyx's Strong Quarter Bolsters New CEO
Tony Coles' tenure got off to the right start with strong earnings and meaningful financial guidance.
Related Topics: Drugs | Health Care | Biotech | Earnings
07:28AM 05/07/08
Discovery Labs Holds Out Hope for Surfaxin
The stock Monday regains some of its sharp Friday losses on the company's positive response to FDA delays. But is the reaction overly optimistic?
Related Topics: Biotech | Drugs | Health Care
11:53AM 05/05/08
Feuerstein's Biotech-Stock Mailbag
Outlooks for SuperGen's Dacogen and Myriad Genetics' Flurizan; more Q&A on ImClone's Erbitux, and more.
Related Topics: Biotech | Health Care | Drugs
11:10AM 05/03/08
Biotech Notebook: Progenics, Wyeth, Introgen
Projecting potential market share for newly approved Relistor; monitoring exec moves at Introgen; and more.
Related Topics: Biotech | Health Care | Drugs
09:26AM 04/30/08
Discovery Labs Awaits FDA Word on Surfaxin
A regulatory decision on the lung treatment could come May 1, but even with approval the biotech will have to work for every bit of upside.
Related Topics: Biotech | Health Care | Drugs
02:02PM 04/29/08
Another Rituxan Setback for Biogen, Genentech
The drug failed to benefit patients with lupus, according to new late-stage study data.
Related Topics: Biotech | Drugs | Health Care
10:12AM 04/29/08
Vertex Hep C Drug Still Leads Schering
Data presented this weekend show telaprevir is the leader.
Related Topics: Drugs | Biotech | Health Care
08:47PM 04/27/08
Feuerstein's Biotech-Stock Mailbag
What to expect when ImClone presents the latest Erbitux data at ASCO in June.
Related Topics: Biotech | Health Care | Drugs
09:57AM 04/26/08
FDA's OK of Relistor Bodes Well for Progenics
News that the drug had been OK'd pushed shares significantly higher.
Related Topics: Health Care | Drugs | Biotech
07:56AM 04/25/08
